Moreover, the FLAURA trial (NCT02296125) has revolutionized the treatment paradigm by demonstrating that osimertinib is superior to the first-generation EGFR-TKIs (Gefitinib/Erlotinib) as first-line treatment for patients with metastatic NSCLC harboring EGFR Ex19del or L858R mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.